why choose us

First received: February 15, 2023

Clinical Trial: A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Locally Advanced Biliary Tract Cancer
Metastatic Biliary Tract Cancer

Study Type: INTERVENTIONAL


Official Title: Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, P

Brief Summary: The objective of this study is to investigate the safety and tolerability of camrelizumab combined with apatinib and chemotherapies (gemcitabine and cisplatin) in patients with advanced biliary tract cancer (BTC).

Read more